Antibiotic adjuvants blocking host-cell invasion pathways represents a promising new direction in periodontitis management

Porphyromonas gingivalis can evade antibiotics by invading host cells, contributing to recurrent periodontitis and persistent tissue damage. A new study reveals that blocking host-cell invasion pathways significantly reduced infection. Simvastatin, a widely used cholesterol-lowering drug, emerged as an effective antibiotic adjuvant, enhancing bacterial clearance, promoting bone-forming activity, and improving treatment outcomes in a rat model of periodontitis. The findings highlight the importance of antibiotic adjuvants in periodontitis treatment.

Periodontitis is a chronic inflammatory disease caused by bacterial infection and an imbalance in the community of microorganisms beneath the gums. Although conventional treatments target dental plaque bacteria, they often fail to completely eliminate the infection. One reason is that Porphyromonas gingivalis (P. gingivalis), a major periodontal pathogen, can invade and hide inside host cells, allowing it to evade antibiotics and later re-emerge to cause recurrent disease.

To address this challenge, a research team led by Professor Cun-yu Wang from the Institute of Advanced Clinical Medicine, Peking University, investigated a host-directed therapeutic strategy that prevents P. gingivalis from invading host cells rather than directly targeting the bacteria. The researchers also evaluated the potential of combining simvastatin or YH-306 with metronidazole, a commonly prescribed antibiotic for periodontitis. Their findings were published in Volume 18 of the International Journal of Oral Science on July 9, 2026.

“The core of this strategy lies in applying host-directed adjuvant therapy to interfere with the pathogenic process. Using adjuvants to block bacterial adhesion and invasion is often considered as a promising, host-directed therapeutic strategy,” says Prof. Wang. “For our study, we evaluated the efficacy of several invasion inhibitors as antibiotic adjuvants in periodontal host cells.”

The study examined four compounds with distinct mechanisms of action, each for a specific host target that P. gingivalis uses during infection. FT011 was used to target type I collagen, ATN-161 to inhibit integrin β1, YH-306 to suppress focal adhesion kinase signaling, and simvastatin, a widely prescribed cholesterol-lowering drug, to reduce lipid raft formation on host cell membranes. Using human oral keratinocytes and periodontal ligament stem cells (PDLSCs), the researchers established laboratory models of P. gingivalis infection and evaluated how effectively these compounds could interfere with bacterial invasion.

Among the tested agents, simvastatin and YH-306 emerged as particularly promising candidates. Both significantly reduced bacterial adhesion and invasion while maintaining favorable safety profiles in host cells. Simvastatin showed an additional advantage, as it enhanced the ability of host cells to clear bacteria that had already entered cells. The treatment also restored the osteogenic potential of infected PDLSCs, helping reverse the negative effects of infection on bone-forming activity. Since destruction of the supporting bone around teeth is a hallmark of periodontitis, this finding could have important therapeutic implications.

To explore the potential of these host-directed agents as antibiotic adjuvants, the team combined the host-targeting compounds with commonly used periodontal antibiotics, including metronidazole, tetracycline, and amoxicillin. The results revealed notable synergistic effects. Simvastatin reduced the amount of metronidazole needed to suppress intracellular bacteria by more than 40% and nearly halved the required tetracycline dose. FT011 showed the strongest synergy with amoxicillin, reducing the required antibiotic dose by more than 50%.

The host-directed compounds also reduced invasion by other clinically relevant periodontal pathogens, including Fusobacterium nucleatum and Aggregatibacter actinomycetemcomitans. This suggests that targeting host invasion pathways may represent a broader strategy for combating polymicrobial periodontal infections rather than focusing on a single bacterial species.

To determine whether these laboratory findings translated into real-world therapeutic benefits, the researchers tested the approach in a rat model of periodontitis. Animals receiving combined treatment with metronidazole and either simvastatin or YH-306 showed substantially improved outcomes compared with antibiotic treatment alone. The combination therapies reduced bacterial burden, limited inflammatory responses, preserved alveolar bone structure, and decreased bone resorption. Among the tested regimens, the simvastatin–metronidazole combination produced the most pronounced benefits, significantly improving bone volume and reducing intracellular bacterial reservoirs.

“Our study highlights an emerging concept in infectious disease treatment, as the approach can reduce antibiotic requirements, limit the development of antimicrobial resistance, and preserve beneficial microbial communities,” explains Prof. Wang.

Although additional research is needed to optimize drug delivery and confirm long-term safety and efficacy in humans, the findings suggest that host-directed antibiotic adjuvants could represent a new frontier in periodontal therapy. By preventing bacteria from invading host cells while simultaneously enhancing tissue regeneration, this strategy may offer a more effective way to break the cycle of recurrent infection and progressive periodontal destruction.


Reference
Title of original paper: P. gingivalis-host interactions direct antibiotic adjuvants for
periodontitis antimicrobial therapy
Journal: International Journal of Oral Science
DOI: https://doi.org/10.1038/s41368-026-00448-1

About Peking University
Founded in 1898 as the Imperial University of Peking, Peking University (PKU) is China’s first national comprehensive university. Located in Beijing, it is a global academic powerhouse consistently ranked among the top universities in Asia and the world It has six faculties, namely Humanities, Social Sciences, Economics and Management, Science, Information Technology and Engineering, as well as Health Science. It consists of 55 schools and departments, 60 research entities, and ten affiliated hospitals. By optimizing disciplines and specialties, it remains a premier institution for research and international exchange in the current times.
Website: https://english.pku.edu.cn/

About Professor Cun-yu Wang from Peking University, China
Dr. Cun-yu Wang serves as an Adjunct Professor at the Institute of Advanced Clinical Medicine, Peking University. He studied at Nanjing Medical University and Peking University’s School of Dentistry, where he obtained his undergraduate and doctoral degrees in 1985 and 1989, respectively. He primarily engages in cutting-edge research on the molecular pathogenesis of oral diseases and was the first to discover TNF-activated nuclear factor kappa B. He has published more than 200 peer-reviewed papers in prestigious journals, including Science, Cell, Nature Biotechnology, and Nature Medicine.

Funding information
This study was supported by the Beijing Natural Science Foundation (Grant Nos. L222144, L242158, and L246035) and Peking University Third Hospital Fund for Interdisciplinary Research (BYSYJC2025057).